Damora Therapeutics (DMRA) Return on Capital Employed (2020 - 2026)
Damora Therapeutics (DMRA) posted Return on Capital Employed of 63.9% for Q1 2026, up 64.98% on a QoQ basis from 182.47% in Q4 2025, and up 6661.0% year-over-year from 0.95% in Q1 2025.
Damora Therapeutics (DMRA) Return on Capital Employed (2020 - 2026) Analysis & Trends
Damora Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 63.9% for Q1 2026.
- Quarterly Return on Capital Employed rose 6661.0% year-over-year to 63.9% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63.9% (up 6661.0% YoY) and the FY2025 annual result came in at 177.56%, down 9349.0% from the prior year.
- Return on Capital Employed was 63.9% for Q1 2026 at Damora Therapeutics, up from 182.47% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 51.32% in Q1 2022 and bottomed at 182.47% in Q4 2025.
- A 5-year average of 107.3% and a median of 104.17% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed plunged 7456 bps — and 2026, when it surged 6661 bps.
- Damora Therapeutics' Return on Capital Employed stood at 92.03% in 2022, then fell by 13 bps to 104.17% in 2023, then decreased by 12 bps to 116.83% in 2024, then slumped by 56 bps to 182.47% in 2025, then soared by 65 bps to 63.9% in 2026.
- Business Quant data shows DMRA's Return on Capital Employed at 63.9% in Q1 2026, 182.47% in Q4 2025, and 169.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | -63.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.90% |
| Dec 31, 2025 | -182.47% |
| Sep 30, 2025 | -169.73% |
| Jun 30, 2025 | -142.55% |
| Mar 31, 2025 | -130.51% |
| Dec 31, 2024 | -116.83% |
| Sep 30, 2024 | -95.17% |
| Jun 30, 2024 | -101.51% |
| Mar 31, 2024 | -103.61% |
| Dec 31, 2023 | -104.17% |
| Sep 30, 2023 | -111.79% |
| Jun 30, 2023 | -110.64% |
| Mar 31, 2023 | -105.31% |
| Dec 31, 2022 | -92.03% |
| Sep 30, 2022 | -77.86% |
| Jun 30, 2022 | -64.74% |
| Mar 31, 2022 | -51.32% |
| Dec 31, 2021 | -41.95% |
| Sep 30, 2021 | -36.92% |
| Jun 30, 2021 | -31.96% |